Product Description
Mechanisms of Action: OXTR Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Topical,Nasal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Obstetric Labor, Premature
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MERMAID | P2 |
Terminated |
Obstetric Labor, Premature |
2022-11-11 |
24% |